All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.

The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your MPN Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

AML Hub

AML Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

Lymphoma Hub

Lymphoma Hub

Multiple Myeloma Hub

Multiple Myeloma Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.

Brought to you by

Scientific Education Support logo
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact
TypesTherapeuticsCongressesTrialsExpert OpinionsEducational ResourcesDRUG UPDATES
2023-10-24T07:49:18.000Z

What are the management considerations for accelerated- and blast-phase MPN?

By Oscar Williams
Featured
Olatoyosi Sobulo Odenike
Oct 24, 2023
Share:
Learning objective: After reading this, learners will be able to cite a new clinical development in accelerated- and blast-phase MPN.

During the 2023 Society of Hematologic Oncology (SOHO) annual congress, the MPN Hub was pleased to speak to Olatoyosi Sobulo Odenike, University of Chicago, Chicago, US. We asked, what are the management considerations for accelerated- and blast-phase MPN?

What are the management considerations for accelerated- and blast-phase MPN?

In the interview, Odenike outlines the characteristics of accelerated- and blast-phase MPN and highlights important management considerations, including key diagnostic and cytogenetic tests. Odenike concludes by discussing treatment goals and the increasing importance of clinical trials for this patient population.

More about...
MPN blast phaseMyeloproliferative neoplasmsSOHO 2023

Your opinion matters

HCPs, what is your preferred format for educational content on the MPN Hub?
11 votes - 10 days left ...

Related articles

Add bookmark

Impact of thrombosis on disease progression and mortality in polycythemia vera

Here, we summarize a retrospective analysis of a large cohort of patients with PV that estimated transitions between disease states and evaluated the impact of incident...

Jan 25, 2024
Add bookmark

Impact of thrombosis on disease progression and mortality in polycythemia vera

Here, we summarize a retrospective analysis of a large cohort of patients with PV that estimated transitions between...

Jan 25, 2024
Add bookmark

Single-cell analysis at ASH: Drivers of leukemic transformation

Around 10–20% of patients with myeloproliferative neoplasms (MPN) eventually develop secondary acute myeloid leukemia (sAML) and are faced with a poor prognosis. Certain mutations...

Feb 12, 2022
Add bookmark

Single-cell analysis at ASH: Drivers of leukemic transformation

Around 10–20% of patients with myeloproliferative neoplasms (MPN) eventually develop secondary acute myeloid leukemia (sAML) and are...

Feb 12, 2022

Newsletter

Subscribe to get the best content related to MPN delivered to your inbox